Science Oct 17, 2026 · Intermediate

Psilocybin and Aging: The Surprising Science of Magic Mushrooms for Longevity

MK
Matt Kaeberlein
Matt Kaeberlein · Published Oct 17, 2026
Length
58:48
Level
Intermediate
AI-generated · This summary was generated by AI.
Source: Full video on the creator’s YouTube channel. The summary below is YoLongevity’s editorial work. · Published Oct 17, 2026 Open original
The full transcript is not shown — for copyright reasons we publish only the embedded video, summary and key quotes.
The gist in 20 seconds

The researchers behind the first work connecting psilocybin to the biology of aging share how a curiosity-driven idea became striking laboratory data. Psilocin extended the lifespan of senescent cells, and monthly psilocybin kept aged mice thriving long past the point where untreated animals reached median survival. The team is now launching a human healthy-aging trial and exploring effects on skin, hair and inflammation far beyond the brain.

Overview

Matt Kaeberlein sits down with Louise and Kasuke, the researchers behind the first studies connecting psilocybin to the biology of aging. Louise explains how a workout buddy's fascination with mushrooms sent her down a four-hour PubMed rabbit hole, where reports of a single dose producing effects years later made her suspect that aging biology might be involved. Kasuke, whose background was in lung cell biology, recounts his initial skepticism about studying a psychedelic for longevity and how the durable molecular effects won him over.

The starting point was the telomere hypothesis: positive psychological states correlate with longer telomeres, and since psilocybin eases anxiety and depression, it might also touch aging biology. In replicative-senescence cell models, psilocin — psilocybin's active metabolite — produced a reproducible, dose-dependent extension of cellular lifespan. The team then moved to aged mice, dosing monthly starting at 19 months; when regulators required the study to stop at median survival of the controls, roughly 80% of treated mice were still thriving.

Multi-omic analysis of banked tissues showed a shift toward a younger transcriptional state across every organ, with the strongest and most consistent signal being potent anti-inflammatory effects, while microdosing most visibly improved skin and hair. The conversation closes on a first human healthy-aging trial called Long Life, the promise of non-brain-penetrant derivatives, and the funding and regulatory barriers that have left this molecule so understudied. Nothing here is medical advice — it is an early, fast-moving research story.

Key quotes

5
2:30
I thought I was going to be reading for 15 minutes, and four hours later I was still reading.
Louise on falling down the psilocybin research rabbit hole.
7:00
Why would we study a psychedelic in the context of aging or longevity? It was a crazy idea to me.
Kasuke on his initial skepticism as a lung-biology researcher.
18:30
It was very reproducible and dose dependent — we see this incredible, striking increase in cellular life extension.
Louise on the very first cell-culture result with psilocin.
31:00
80% of the psilocybin mice were still thriving.
Louise on the aged-mouse study when the control group reached median survival.
48:00
The systemic impacts of psilocybin outside the brain might actually turn out to be as or more important than its impacts on the brain.
Kasuke on the surprising multi-organ findings.

Key ideas

9
2:30

A workout-buddy question became a research program

Louise's gym friend Aaron kept asking science questions about magic mushrooms. A planned 15-minute search turned into a four-hour deep dive, and reports of single doses producing years-long effects made her wonder whether aging biology was the explanation.

7:00

From skepticism to scientific curiosity

Kasuke, whose work had focused on lung cell biology and inflammation, first saw psychedelics only through their recreational reputation. The idea that a short exposure could leave lasting molecular effects, plus psilocybin's FDA breakthrough status, made the question genuinely interesting.

11:00

The telomere hypothesis

A correlation runs through the literature: positive psychological states track with longer telomeres, negative states with shorter ones. Because psilocybin eases anxiety and depression, the team hypothesized it might influence telomere and aging biology — and set out to test it.

15:30

Psilocin is what the body actually sees

Ingested psilocybin is broken down into psilocin, its active metabolite, which is what cells encounter systemically. It signals through the serotonin receptor — and that receptor sits on almost every cell in the body, not only in the brain.

18:30

Striking life extension in cells

In the lab's standard replicative-senescence models, treating cells with psilocin produced a reproducible, dose-dependent increase in cellular lifespan. This first hard data point justified the leap to animal work.

25:30

A realistic protocol in aged mice

The team started treatment in 19-month-old mice, roughly equivalent to a 60-year-old person, dosing once a month to approximate a plausible once-a-year human cadence. The protocol was built from careful cross-species dose extrapolation on a shoestring budget.

31:00

Aged mice kept thriving

Animal-care rules allowed the study to run only until a group reached median survival. When the control group hit 50% mortality, roughly 80% of the treated mice were still alive and well — a striking lifespan signal, even though the full curve could not be completed.

44:00

The body, not just the brain

Proteomic, metabolomic and transcriptomic profiling showed psilocin shifting tissues toward a younger transcriptional state across every organ tested, measured a week after the last dose. The strongest, most consistent signal was a potent anti-inflammatory effect; microdosing most visibly improved skin and hair.

52:00

A first human healthy-aging trial

A trial called Long Life, funded through the Vail behavioral-health foundation, will give healthy adults aged 60 to 85 full doses of psilocybin, using epigenetic clocks and other biological-age measures as endpoints. Enrollment is anticipated to begin in November.

Practical takeaways

6
  • 1

    Mind and body are linked in the data 11:00

    The whole program grew from the observation that positive psychological states track with healthier aging markers — a reminder that mental well-being is woven into the longevity picture.

  • 2

    Follow the data, not the hype 18:30

    The team repeats that it makes decisions only from reproducible results — a useful lens for anyone weighing bold wellness claims about any compound.

  • 3

    Effects may reach skin and hair 39:00

    In mice, microdosing most visibly improved skin health and coat, hinting that the body-wide story may be broader than the brain and worth watching as research matures.

  • 4

    Taming chronic inflammation is a recurring theme 44:00

    The strongest signal across organs was anti-inflammatory, echoing much of longevity science: keeping age-related, low-grade inflammation in check appears again and again as a thread worth caring about.

  • 5

    Medicinal and recreational use are not the same 56:00

    The researchers stress that supervised, medical settings differ profoundly from casual use, and caution against untrained 'guides.' This is a research story, not a how-to.

  • 6

    Biological-age tests are tools, not verdicts 54:00

    No single clock is perfect, and even fasting status can skew a score. Capturing several dimensions gives a fuller picture than relying on any one number.

Topics & chapters

14
0:00

Introduction

Matt Kaeberlein welcomes Louise and Kasuke to talk about an unexpected link between psilocybin and aging.

2:30

How a magic-mushroom question started it all

Louise's workout buddy, a four-hour PubMed session, and the puzzle of years-long effects from a single dose.

7:00

A co-author's initial skepticism

Kasuke recalls dismissing the idea of studying a psychedelic for longevity before the science drew him in.

11:00

The telomere hypothesis

Why correlations between psychological state and telomere length pointed the team toward aging biology.

15:00

Schedule-1 hurdles and psilocin

The paperwork of working with a controlled substance, and the shift from psilocybin to its active metabolite psilocin.

18:30

First cell experiment: life extension

Reproducible, dose-dependent extension of cellular lifespan in replicative-senescence models.

22:00

Mechanism and the serotonin receptor

How a receptor present on nearly every cell could explain effects far from the brain, and what remains unpublished.

25:30

Designing the aged-mouse lifespan study

Starting at 19 months with monthly dosing, built from careful cross-species extrapolation on limited funding.

31:00

Stopped at median survival

Why the study had to end when controls reached 50% mortality, with ~80% of treated mice still thriving.

35:00

Flies, worms and future survival studies

A Cohen Foundation grant, rapid protocol testing in C. elegans and Drosophila, and the question of strain choice.

39:00

Microdosing, skin and hair

A low-dose protocol showing modest survival benefit and a dramatic reduction in age-related skin problems.

43:00

Beyond the brain: systemic effects and derivatives

Why peripheral organs may matter more than the brain, and non-brain-penetrant derivatives as a tool to test it.

47:30

Multi-omics: a shift toward youth

Tissue-wide transcriptional rejuvenation and a potent anti-inflammatory signature, with parallels to mTOR inhibition.

52:00

The human trial, biomarkers and closing

The Long Life trial at Vail, epigenetic clocks and other biological-age readouts, and the case for more funding and sane regulation.

People mentioned

Matt KaeberleinLouiseKasukeAaronChuck RaysonHan J Lee